11.22.24 -- From Bike Mechanic To Surgeon To CEO

In August 2024, the FDA greenlighted the first TCR cell therapy to be approved for use in the U.S. for patients with resectable or metastatic synovial sarcoma who have previously received chemotherapy. It marked the first new treatment for those patients in more than a decade. On the Business of Biotech, we get to know Adrian Rawcliffe, CEO of Adaptimmune, the therapy’s developer and manufacturer, and why he’s all-in on cell therapies.

Explore the challenges behind the perceived simplicity of mRNA process development, as well as characterization strategies and models for predicting process outcomes at early stages.

Educational animation in clinical trials enhances patient understanding, health literacy, and retention, addressing diverse literacy needs by simplifying complex information into engaging visual content.

Investing in employee training and development is not just beneficial for the employees. It also contributes significantly to the organization’s success and competitive advantage.

Discover how the Pharmacological Audit Trail (PhAT), an evidence-based framework, can streamline your drug development process, optimize dose selection, and enhance regulatory success.

AI promises faster drug development, but challenges like the Black Box Dilemma, data bias, and over-reliance on automation threaten its potential.